Determining antimicrobial resistance to Chlamydia trachomatis and applying present findings in daily practice;OdreCrossed d signivanje antimikrobne rezistencije Chlamydia trachomatis i primjena dosadašnjih spoznaja u svakodnevnoj praksi

Medicinski Glasnik

Volumn 7, Issue 1, 2010, Pages 26-31

  Sternak, Sunčanica Ljubin ^a   Kerk, Vi Nja ^b  

^a Hrvatski zavod za Javno Zdravstvo   (Croatia)

^b Croatia   (Croatia)

Author keywords

C. trachomatis; Cultivation; Heterotypic resistance

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHLAMYDIA TRACHOMATIS; CLINICAL PRACTICE; IN VITRO STUDY; NONHUMAN; REVIEW; URINARY TRACT INFECTION; CHLAMYDIASIS; DRUG EFFECT; HUMAN; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; SEXUALLY TRANSMITTED DISEASE;

CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; SEXUALLY TRANSMITTED DISEASES, BACTERIAL;

EID: 77952338896     PISSN: 18400132     EISSN: 18402445     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Surveillance 2005. Atlanta, GA: U.S. Department of Health and Human Services, 2006.
2. Sternak SL, Kružić V, Vilibić Čavlek T, Škerk V. Chlamydia trachomatis infection in Croatian symptomatic and asymptomatic men. Journal of men's health & gender 2006; 3:80-1.
3. Škerk V, Markovinović L, Zekan S, Jakšić J, Židovec Lepej S, Markotic A, Škerk V, Radošević V, Cvitković L, Begovac J. The significance of Chlamydia trachomatis in urethritis and prostatitis - differences in therapeutic approach - Croatian experience. J Chemother 2009; 21:63-7.
4. Ujević B, Habek JC, Habek D. Prevalence of infection with Neisseria gonorrhoeae or Chlamydia trachomatis in acute mucopurulent cervicitis. Arh Hig Rada Toksikol 2009; 60:197-203.
5. Hiršl-Hećej V, Šikanić-Dugić N, Domljan LM, Pustišek N, Kani D, Žele-Starčević L. Chlamydia trachomatis u adolescentica i mladih žena. U: Knjiga sažetaka 9-og simpozija o spolno prenosivim bolestima i urogenitalnim infekcijama, Opatija, Hrvatska, 2007. Sažetak 33, str.40-1. Hrvatsko društvo za urogenitalne i spolno prenosive infekcije HLZ-a, Zagreb, Hrvatska, 2007.
6. Hiršl-Hećej V, Pustišek N, Sikanić- Dugić N, Domljan LM, Kani D. Prevalence of Chlamydial genital infection and associated risk factors in adolescent females at an urban reproductive health care center in Croatia. Coll Antropol 2006; 30(Suppl 2):131-7.
7. Schachter J, Stoner E, Moncada J.Screening for chlamydial infections in women attending family clinics. West J Med 1983; 138:375-9.
8. Stamm WE, Cole B. Asymptomatic Chlamydia trachomatis urethritis in men. Sex Transm Dis 1986;13:163-5.
9. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Gidelines, 2006. MMWR 2006; 55 (No.RR-11):38.
10. Centers for Disease Control and Prevention. Screening tests to detect Chlamydia trachomatis and Neisseria gonorrhoeae infections-2002. MMWR 2002; 51 (No.RR-15):3.
11. Fredlund H, Falk L, Jurstrand M, Unemo M. Molecular genetic methods for diagnosis and characterization of Chlamydia trachomatis and Neisseria gonorrhoeae: impact on epidemiological surveillance and interventions. APMIS2004; 112:771-84.
12. Martin DH, Nsuami M, Schachter J, Hook III WE, Ferrero D, Quinn TC, Gaydos C. Use of multiple nucleic acid amplification tests to define the infected-patient "gold standard" in clinical trials of new diagnostic tests for Chlamydia trachomatis infections. J Clin Microbiol 2004; 42:4749-58.
13. Ripa T, Nilsson PA. Chlamydia trachomatis strain with a 377-bp deletion in the cryptic plasmid causing false-negative nucleic amplification tests. Sex Transm Dis 2007; 34:255-6.
14. Reischl U, Straube E, Unemo M. The Swedish new variant of Chlamydia trachomatis (nvCT) remains undetected by many European laboratories as revealed in the recent PCR/NAT ring trial organized by INSTAD e.V, Germany. Euro Surveill 2009;14:1-4.
15. Ridgway GL, Owen JM, Oriel JD. A method for testing antibiotic susceptibility of C. trachomatis in a cell culture system. J Antimicrob Chemother 1976; 2:77-81.
16. Lee CK, Bowie WR, Alexander ER. In vitro assay of the efficacy of antimicrobial agents in controlling Chlamydia trachomatis propagation. Antimicrob Agents Chemother 1978; 13:441-5.
17. Stirling P, Richmond S. The developmental cycle of Chlamydia trachomatis in McCoy cells treated with cytochalasin B J Gen Microbiol 1977; 100:31-42.
18. Ehret JM, Judson FN. Susceptibility testing of Chlamyida trachomatis: from eggs to monoclonal antibodies. Antimicrob Agents Chemother 1988; 32:1295-9.
19. Ridgway GL, Owen JM, Oriel JD. The antimicrobial susceptibility of Chlamydia trachomatis in cell culture. Brit J Vener Dis 1978; 54:103-6.
20. Essig A. Chlamydia and Chlamydophila. U: Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA (eds). Manual of Clinical Microbiology. 9th ed. ASM press, Washington, 2007:1021-35.
21. Suchland RJ, Geisler WM, Stamm WE. Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp. Antimicrob Agents Chemother 2003; 47:636-42.
22. Cross NA, Kellock DJ, Kinghorn GR, Taraktchoglou M, Bataki E, Oxley KM, Hawkey PM, Eley A. Antimicrobial susceptibility testing of Chlamydia trachomatis using a reverse transcriptase PCR-based method. Antimicrob Agents Chemother 1999; 43:2311-3.
23. Treharne JD, Yearsley PJ, Ballard RC. In vitro studies of Chlamydia trachomatis susceptibility and resistance to rifampin and rifabutin. Antimicrob Agents Chemother 1989; 33:1393-4.
24. Martens MG, Faro S, Maccato M, Riddle G, Hammill H, Wang Y. In vitro susceptibility testing of clinical isolates of Chlamydia trachomatis. Infect Dis Obstetr Gyn 1993; 1:40-5.
25. Rice RJ, Bhullar V, Mitchell SH, Bullard J, Knapp JS. Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated genital tract infections and pelvic inflammatory disease. Antimicrob Agents Chemother 1995; 39:760-2.
26. Jones RB, Van Der Pol B, Johnson RB. Susceptibility of Chlamydia trachomatis to trovafloxacin. J Antimicrob Chemother 1997; 39(Suppl B):63-5.
27. Johannisson G, Sernryd A, Lycke E. Susceptibility of Chlamydia trachomatis to antibiotics in vitro and in vivo. Sex Trans Dis 1979; 6:50-7.
28. Škerk V, Krhen I, Lisić M Begovac J, Roglić S, Škerk V, Ljubin Sternak S, Banaszak A, Strugar-Šuica J, Vuković J. Comparative randomized pilot study of azithromycin and doxycycline efficacy in the treatment of prostate infection caused by Chlamydia trachomatis. Int J Antimicrob Agents 2004; 24:188-91.
29. Škerk V, Ljubin Sternak S, Roglić S, Škerk V, Lisić M. Diagnosis and treatment of chronic prostatitis caused by Chlamydia trachomatis. J Chemoter 2005; 17: 570-1.
30. Van Vranken M. Prevention and treatment of sexually transmitted disease: an update. Am Fam Physician 2007;76(12):1827-32.
31. Pitsouni E, Iavazzo C, Athanasiou S, Falagas ME. Single-dose azithromycin versus erythromycin or amoxicillin for Chlamydia trachomatis infection during pregnancy: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents 2007; 30:213-21.
32. Dessus-Babus S, Bebear CM, Charron A, Bebear C, de Brbeyrac B. Sequencing of gyrase and topoisomerase IV quinolone-resistance determing regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro. Antimicrob Agents Chemother 1998; 42:2474-81.
33. Dreses-Werringloer U, Padurbin I, Jurgens-Saathoff B, Hudson AP, Zeidler H, Kohler L. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro. Antimicrob Agents Chemother 2000; 44:3288-97.
34. Dreses-Werringloer U, Padurbin I, Zeidler H, Kohler L. Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro. Antimicrob Agents Chemother 2001; 45:3001-8.
35. Morrissey I, Salman H, Bakker S, Farrell D, Bebear CM, Ridgway G. Serial passage of Chlamydia spp. In sub-inhibitory fluoroquinolone concetracions. J Antimicrb Chemother 2002; 49:757-61.
36. Smelov V, Krylova T, Smelova N, Norman L. Azithromycin treatment follow-up:antibacterial susceptibility of Chlamydia trachomatis in patients with chronic prostatitis. Int J Antimicrob Agents 2004; 23S1: S79-82.
37. Siewert K, Rupp J, Klinger M, Silbach W, Gieffers J. Growth Cycle-dependent pharmacodynamics of antichlamydial drugs. Antimicrob Agents Chemother 2005; 49:1852-6.
38. Jones RB, Vander Del Pol B, Martin DH, Shepard MK. Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics. J Infect Dis 1990; 162:1309-15.
39. Lefevre JC, Lepargneur JP, Guion D, Bei S. Tetracycline-resistant Chlamydia trachomatis in Toulouse, France. Pathol Biol 1997; 45:376-8.
40. Somani J, Bhullar VA, Workowski KA, Farshy CE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis 2000; 181:1421-7.
41. Dickinson TM, Archer GL. Phenotypic expression of oxacillin resistance in Staphylococcus epidermidis: roles of mecA transcriptional region and resistant-subpopulation selection. Animicrob Agents Chemother 2000; 44:1616-23.
42. th International Symposium on Human Chlamydial Infection. Napa, Calif, June 21-26,1998. Berkley Universitiy Press, Berkley, California,1998:313-6.
43. Wang S A, Papp JR, Stamm WE, Peeling RW, Martin DH, Holmes KK. Evaluation of antimicrobial resistance and treatment failures for Chlamydia trachomatis. A meeting report. J Infect Dis 2005; 191:917-23.